|Table of Contents|

Case analysis and prognostic factors of stage Ⅰ/Ⅱ extranodal NK/T cell lymphoma（75 cases）

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 12
Page:
2293-2298
Research Field:
Publishing date:

Info

Title:
Case analysis and prognostic factors of stage Ⅰ/Ⅱ extranodal NK/T cell lymphoma（75 cases）
Author(s):
WANG Bingxuan1; WANG Jianhong2; DUAN Xiaohui2; LYU Yao2; WU Zhentian2; WANG Shixiong2; YANG Na1; LU Ming2; GAO Guangxun2; ZHANG Tao2; BAI Qingxian2
1.Xi'an Medical University,Shaanxi Xi'an 710068,China;2.Cardiovascular Department,the First Affiliated Hospital of Air Force Medical University,Shaanxi Xi'an 710032,China.
Keywords:
extranodal NK/T cell lymphoma; stage Ⅰ/Ⅱ; new indicators; prognostic factors
PACS:
R733
DOI:
10.3969/j.issn.1672-4992.2023.12.021
Abstract:
Objective:To investigate the clinical characteristics and treatment options of patients with stage Ⅰ/Ⅱ extranodal NK/T cell lymphoma(ENKTL),and to analyze the factors affecting the prognosis of patients.Methods:The clinical date of patients with ENKTL,Ⅰ/Ⅱ stage from 2012 to 2020 was collected and retrospectively analyzed to analysis of the recent efficacy and long-term prognosis of chemotherapy and chemotherapy combined with radiotherapy and explore the effects of new evaluation indicators on patient survival and prognosis.Results:Seventy-five patients with stage Ⅰ /Ⅱ ENKTL were collected,median age was 41 years old,male and female ratio is 2.1∶1.The Ann Arbor staging Ⅰ and stageⅡ were 64.0% and 36.0%,CA staging system were staging Ⅰ,Ⅱ and Ⅲ were 44.0%,5.3% and 50.7%.The first-line chemotherapeutic regimens includes P-Gemox and MESA,studies have shown with 42.7% of patients achieving complete resection（CR),14.7% of patients achieving（PR).In contrast,those patients using the MESA regimen was significantly increased who diagnosed Ann Arbor stage Ⅱ,have Ki-67≥65%,stage Ⅲ of CA,and have B symptoms.Thirty-nine patients（52.0%) were relapsed and refractory,and 13 patients were treated with PD-1 monoclonal antibody+chidamide,of whom the 2-year PFS and OS were 100.0% in the 8 patients who continued maintenance therapy with the original regimen after remission.All patients were followed up for a median of 43 months.The OS rates at 2,5 years were 95.0%,70.7%,respectively.Univariate analysis showed that the copy number of EBV-DNA（P=0.002,P=0.002) was a poor prognostic factor in ENKTL.COX regression model analysis showed that a high level of platelet to lymphocyte ratio（PLR)（P=0.005) was negatively associated with patient prognosis.Conclusion:The CA stage system and PINK-E score seems more accurate than others in disease stratification.High PLR may become a new indicator of poor prognosis in ENKTL patients.Survival of patients with elderly,extranasal disease site,have B-symptoms,high LDH and high PLR indeed have been improved by chemotherapy based on P-Gemox regimen and MESA regimen.New drugs such as PD-1 monoclonal antibody or chidamide bring new treatment options for refractory and recurrent patients.

References:

［1］MONTES MOJARRO IA,CHEN BJ,RAMIREZ IBARGUEN AF,et al.Mutational profile and EBV strains of extranodal NK/T-cell lymphoma,nasal type in Latin America［J］.Modern Pathology,2020,33(5):781-791.
［2］CELESTE SANCHEZ-ROMERO,RONELL BOLOGNA-MOLINA,OSLEI PAES DE ALMEIDA,et al.Extranodal NK/T cell lymphoma,nasal type:an updated overview［J］.Critical Reviews in Oncology Hematology,2021,1(159):103237-103249.
［3］TSE E,KWONG YL.NK/T-cell lymphomas［J］.Best Practice and Research Clinical Haematology,2019,32(3):253-261.
［4］MIHAIELA LUNGU,ANCA TELEHUZ,DOINA CARINA VOINESCU,et al.NK/T-cell non-Hodgkin lymphoma:case report and review of the literature［J］.Experimental and Therapeutic Medicine,2021,21(1):91-96.
［5］JEEYUN LEE,CHEOLWON SUH,YEON HEE PARK,et al.Extranodal natural killer T-cell lymphoma,nasal-type:prognostic model from aretrospective multicenter study［J］.Journal of Clinical Oncology,2006,24(4):612-618.
［6］YANG Y,ZHANG YJ,ZHU Y,et al.Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma,nasal-type:a multicenter study［J］.Leukemia,2015,29(7):1571-1577.
［7］R SUZUKI,J SUZUMIYA,M YAMAGUCHI,et al.Prognostic factors for mature natural killer（NK) cell neoplasms:aggressive NK cell leukemia and extranodal NK cell lymphoma,nasal type［J］.Ann Oncol,2010,21(5):1032-1040.
［8］HONG H,LI Y,LIM ST,et al.A proposal for a new staging system for extranodal natural killer T-cell lymphoma:a multicenter study from China and Asia lymphoma study group［J］.Leukemia,2020,34(8):2243-2248.
［9］YOON SE,SONG Y,KIM SJ,et al.Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients:a multinational,multicenter,prospective registry study in Asia［J］.The Lancet Regional Health Western Pacific,2021,22(10):100126-100136.
［10］李小秋,李甘地,高子芬,等．中国淋巴瘤亚型分布:国内多中心性病例10002例分析［J］.诊断学理论与实践,2012,11(2):111-115. LI XQ,LI GD,GAO ZF,et al.Distribution of lymphoma subtypes in China:analysis of 10002 domestic multicenter sexual cases［J］.Theory and Practice of Diagnostics,2012,11(2):111-115.
［11］SUN J,YANG Q,LU Z,et al.Distribution of lymphoid neoplasms in China:analysis of 4638 cases according to the world health organi-zation classification［J］.American Journal of Clinical Pathology,2012,138（3):429-434．
［12］LIANG R,WANG Z,BAI QX,et al.Natural killer/T cell lymphoma,nasal type:a retrospective clinical analysis in North-Western China［J］.Oncology Research and Treatment,2016,39(1-2):45-52.
［13］YANG QP,ZHANG WY,YU JB,et al.Subtype distribution of lymphomas in Southwest China:analysis of 6,382 cases using WHO classification in a single institution［J］.Diagnostic Pathology,2011,22(6):77-87.
［14］魏冲,张炎,王为,等.单中心结外 NK /T 细胞淋巴瘤患者临床特点及基于培门冬酶化疗的预后分析［J］.中国实验血液学杂志,2021,29(3):735-740. WEI C,ZHANG Y,WANG W,et al.Clinical characteristics and prognostic analysis of NK/T-cell lymphoma patients treated with pegaspargase based chemotherapy［J］.Journal of Experimental Hematology,2021,29(3):735-740.
［15］张巍,韩金芬,闫秀明,等.结外NK/T细胞淋巴瘤的临床特征和预后分析［J］.临床医药文献电子杂志,2020,7(71):15-18. ZHANG W,HAN JF,YAN XM,et al.Clinical features and prognostic analysis of extranodal NK/T-cell lymphoma［J］.Journal of Clinical Medical Literature,2020,7(71):15-18.
［16］HIROSHI KIMURA,YOK-LAM KWONG.EBV viral loads in diagnosis,monitoring,and response assessment［J］.Front Oncol,2019,12(9):62-68.
［17］CHARLOTTE SYRYKH,SARAH PERICART,CLAIRE LAMAISON,et al.Epstein-barr virus-associated T-and NK-cell lympho proliferative diseases:A review of clinical and pathological features［J］.Cancers,2021,13(13):3315-3331.
［18］YANG Y,ZHU Y,CAO JZ,et al.Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma:analysis from a multicenter study［J］.Blood,2015,126(12):1424-1432.
［19］LIU X,WU T,ZHU SY,et al.Risk-dependent conditional survival and failure hazard after radiotherapy for early-stage extranodal nat-ural killer/T-cell lymphoma［J］.Jama Network Open,2019,2(3):190194-190209.
［20］GAO Y,ZHANG YJ,WANG XX,et al.Novel induction therapy for newly diagnosed extranodal natural killer/T cell lymphoma（ENKTL) treated by anti-PD-1 antibody plus histone deacetylase inhibitor followed by P-Gemox regimen［J］.Blood,2021,138(Supplement 1):137-143.
［21］KIM TM,LEE SY,JEON YK,et al.Clinical heterogeneity of extranodal NK/T-cell lymphoma,nasal type:a national survey of the Korean cancer study group［J］.Ann Oncol,2008,19(8):1477-1484.
［22］KIM SJ,YOON DH,JACCARD A,et al.A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment:a multicentre,retrospective analysis［J］.Lancet Oncol,2016,17(3):389-400.
［23］MANTOVANI A,ALLAVENA P,SICA A,et al.Cancer-related inflammation［J］.Nature,2008,454(7203):436-444.
［24］CHEN Y,ZHANG ZX,FANG Q,et al.Cancer cell international for prognostic impact of platelet-to-lymphocyte ratio on diffuse large B-cell lymphoma:a meta-analysis［J］.Cancer Cell International,2019,24(19):1-10.
［25］TAO YX,HE XH,QIN Y,et al.Leuk lymphoma for low platelet/platelet distribution width and high platelet/lymphocyte ratio are adverse prognostic factors in patients with newly diagnosed advanced Hodgkin lymphoma［J］.Leuk Lymphoma,2021,62(13):3119-3129.
［26］XIONG J,CUI BW,WANG N,et al.Genomic and transcriptomic characterization of natural killer T cell lymphoma［J］.Cancer Cell,2020,37(3):403-419.

Memo

Memo:
-
Last Update: 1900-01-01